Finch Therapeutics has joined the ranks of biotechs that are narrowing their focus. With its lead program under clinical hold, the microbiome specialist has pulled out of a planned study in chronic ...
A week after taking back two unhatched inflammatory bowel assets from Takeda, Finch Therapeutics is cutting more than a third of its staff and delaying clinical trial plans to stave off rising costs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback